Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
Publication stageIn Press Accepted Manuscript
The advisory board meeting that inspired this publication was supported by Pfizer, Inc. (New York, NY).
All authors participated in the advisory board that discussed the issues presented in this paper. Authors did not receive payment for development of the manuscript.
Jerry Vockley is a member of the board of directors of the ACMG; Nicola Brunetti-Pierri has received consulting fees from Ultragenyx and Genespire; Wendy K Chung has received consulting fees as a member of the Regeneron Genetics Center-scientific advisory board, and is a member of the board of directors of Prime Medicine; Angus J Clarke has a consultancy agreement with Pfizer Inc. and with EspeRare and Pierre Fabre; Nina Gold is supported by National Institutes of Health grant TR003201 , the Eleanor and Miles Shore Family Award and the Greenwall Foundation, she has received consulting fees from RCG Consulting; Pfizer and Newspring Capital, LLC, and is a member of the ACMG Policy and Practice Guidelines Committee; Robert C Green is supported by National Institutes of Health grants U01 TR003201, R01 HL143295, R01 HG009922, RF1 AG047866, U19 HD077671, he is the cofounder of Genome Medical, and has received consulting fees from AIA, Allelica, Fabric, GeneStory, Genome Web, Genomic Life, Grail, and Verily; Stephen Kagan, Tara Moroz are employees of Pfizer Inc and own stock in Pfizer Inc.; Christian P Schaaf has received consultancy fees from Pfizer Inc for participation in this advisory board; Martin Schulz is an employee of Pfizer Inc.; Elfride De Baere is an unpaid member of the Foundation Fighting Blindness (FFB) Scientific Advisory Board, she has received consulting fees from Novartis, Janssen Global Services, and Pfizer Inc., and she is Senior Clinical Investigator of the Research Foundation-Flanders (FWO) (1802220N).